Neuren Pharmaceuticals Limited

NEU

NZNEUE0001S8

Pharmaceuticals

Market Closed - Australian S.E. Other stock markets 07:10:06 16/07/2024 BST			5-day change	1st Jan Change
20.99 ^AUD	+2.64%		+7.64%	-15.94%

05-28	Transcript : Neuren Pharmaceuticals Limited - Shareholder/Analyst Call
05-27	Neuren Phase 2 Trial Shows Significant Improvements in Pitt Hopkins Syndrome	CI

Neuren Pharmaceuticals Limited Announces Cessation of Graeme Bruce Howie as Director

June 08, 2012 at 12:05 am

Neuren Pharmaceuticals Limited announced the cessation of Graeme Bruce Howie as director, effective 31 May 2012.

Latest news about Neuren Pharmaceuticals Limited

Transcript : Neuren Pharmaceuticals Limited - Shareholder/Analyst Call	05-28
Neuren Phase 2 Trial Shows Significant Improvements in Pitt Hopkins Syndrome	05-27	CI
Transcript : Neuren Pharmaceuticals Limited - Special Call	05-27
Neuren Pharmaceuticals Partner Acadia Pharmaceuticals Posts US DAYBUE Sales of $75.9 Million	05-09	MT
Neuren Pharmaceuticals Posts AU$243 Million Cash, Short-Term Investments	04-24	MT
Neuren Pharmaceuticals' Medication Secures Priority Review from Health Canada	04-23	MT
Neuren Pharmaceuticals Limited Provides Sales Guidance for the First Quarter and Full Year 2024	02-29	CI
Transcript : Neuren Pharmaceuticals Limited, Q4 2023 Earnings Call, Feb 29, 2024	02-29
Neuren Pharmaceuticals Limited Reports Earnings Results for the Full Year Ended December 31, 2023	02-29	CI
Culper Research discloses short position in Acadia Pharma	02-15	RE
Neuren Pharmaceuticals Completes Recruitment for Phase Two Neurological Trial; Shares Fall 4%	12-20	MT
Neuren Pharmaceuticals Concludes Enrollment for Phase 2 Trial in Pitt Hopkins Syndrome	12-05	MT
Argenica Therapeutics Appoints Nonexecutive Chair	11-30	MT
Neuren Pharmaceuticals Posts Higher Q3 Net Sales in US for Rett Syndrome Treatment	11-03	MT
Neuren Pharmaceuticals Limited(ASX:NEU) added to S&P/ASX 200 Index	18/09/23	CI
Neuren Pharmaceuticals Limited Reiterates Net Sales Guidance for the Third Quarter of 2023	28/08/23	CI
Neuren Pharmaceuticals Limited Reports Earnings Results for the Half Year Ended June 30, 2023	28/08/23	CI
Sector Update: Health Care Stocks Gain Pre-Bell Friday	14/07/23	MT
Sector Update: Health Care	14/07/23	MT
Top Premarket Gainers	14/07/23	MT
ACADIA Pharma Acquires Ex-North America Rights to Trofinetide, Global Rights to NNZ-2591; Shares Surge Premarket	14/07/23	MT
Weaker-than-Expected US Data Spur Rally in Australian Shares	14/07/23	MT
Neuren Pharmaceuticals Jumps 17% After Global Expansion of DAYBUE Partnership	14/07/23	MT
Transcript : Neuren Pharmaceuticals Limited - Special Call	14/07/23
ACADIA Pharmaceuticals Acquires Ex-North America Rights to Trofinetide, Global Rights to NNZ-2591; Shares Rise After Hours	13/07/23	MT

Chart Neuren Pharmaceuticals Limited

Duration

Period

More charts

Neuren Pharmaceuticals Limited is an Australia-based biopharmaceutical company developing therapies for neurodevelopmental disorders. The Company is developing new drug therapies to treat multiple serious neurological disorders that emerge in early childhood and have no or limited approved treatment options. The Companyâs product DAYBUE (trofinetide) is used to treat Rett syndrome in adults and pediatric patients two years of age and older. The United States (US) Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have both granted orphan drug designation to the Company for trofinetide in Fragile X syndrome. Its second product NNZ-2591 is in phase II clinical trials in Phelan-McDermid syndrome, Angelman syndrome, Pitt Hopkins syndrome and Prader-Willi syndrome. The Company has granted an exclusive worldwide license to Acadia Pharmaceuticals Inc. for the development and commercialization of NNZ-259 for Rett syndrome and Fragile X syndrome.

Sector

Pharmaceuticals

Calendar

26/08/2024 - Q2 2024 Earnings Release (Projected)

Related indices

S&P/ASX 200

More about the company

Income Statement Evolution

More financial data

Ratings for Neuren Pharmaceuticals Limited

Trading Rating

Investor Rating

ESG Refinitiv

D+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

20.45 AUD

Average target price

28.56 AUD

Spread / Average Target

+39.65%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
NEUREN PHARMACEUTICALS LIMITED	-15.94%	1.77B
ELI LILLY AND COMPANY	+63.45%	856B
NOVO NORDISK A/S	+39.35%	631B
JOHNSON & JOHNSON	-4.61%	359B
MERCK & CO., INC.	+17.54%	325B
ABBVIE INC.	+8.05%	297B
ROCHE HOLDING AG	+5.56%	234B
NOVARTIS AG	+16.30%	226B
AMGEN INC.	+14.33%	177B
PFIZER, INC.	+1.88%	165B

Other Pharmaceuticals